Cabotegravir for substance-related disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 Sep 2025: Trial registered, NCT07199335
  2. 24 Feb 2026: Trial started, NCT07199335

The trials

NCT07199335: Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

State
Under way
Phase
Phase 4
People
100 planned
Started
24 Feb 2026
Primary completion
Dec 2028
Arms
All participants
Results
None posted
  1. 30 Sep 2025: Trial registered
  2. 24 Feb 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as APRETUDE (cabotegravir), Apretude, Cabenuva component cabotegravir, Cabotegravir (CAB) tablet, Cabotegravir Extended-Release Injectable Suspension, for intramuscular use., Cabotegravir Injectable Suspension, Cabotegravir Injection, Cabotegravir Injection [Apretude], Cabotegravir Oral Tablet, Oral CAB, Oral cabotegravir (CAB).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.